Connect with us

World

US FDA panel backs first-of-a-kind COVID-19 pill from Merck

A panel of US health advisers on Tuesday narrowly backed the benefits of a closely watched COVID-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans could take at home to treat the virus.

A Food and Drug Administration panel voted 13-10 that the drug’s benefits outweigh its risks, including potential birth defects if used during pregnancy.

The group’s recommendation came after hours of debate about the drug’s modest benefits and potential safety issues. Experts backing the treatment stressed that it should not be used by anyone who is pregnant and called on FDA to recommend extra precautions before the drug is prescribed, including pregnancy tests for women of child-bearing age.

For more coronavirus news, visit our dedicated page.

The vote specifically backed the drug for adults with mild-to-moderate COVID-19 who face the greatest risks, including older people and those with conditions like obesity and asthma. Most experts also said the drug shouldn't be used in vaccinated patients, who weren't part of the study and haven't been shown to benefit from the medication.

The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision before year’s end.

The drug, molnupiravir, could provide a much-needed weapon against the virus as colder weather pushes case counts higher and US officials brace for the arrival of the new omicron variant. It is already authorized for emergency use.

Merck hasn’t specifically tested its drug against the new variant but said it should have some potency based on its effectiveness against other strains of coronavirus.

But that uncertainty frustrated many panelists as they grappled with whether to back the treatment for millions of Americans.

“With no data saying it works with new variants I really think we need to be careful about saying that this is the way to go,” said Dr. David Hardy of Charles Drew University School of Medicine and Science, who ultimately voted to back the drug.

The panel’s narrow-but-positive recommendation came despite new data from Merck that paint a less compelling picture of the drug’s effectiveness than just a few weeks earlier.

Last week, Merck said final study results showed molnupiravir reduced hospitalization and death by 30% among adults infected with the coronavirus, when compared with adults taking a placebo. That effect was significantly less than the 50 percent reduction it first announced based on incomplete results.

That smaller-than-expected benefit amplified experts' concerns about the drug's toxicity for human fetuses.

FDA scientists told the panelists earlier Tuesday that company studies in rats showed the drug caused toxicity and birth defects when given at very high doses. Taken together, FDA staffers concluded the data “suggest that molnupiravir may cause fetal harm when administered to pregnant individuals.”

FDA is weighing a blanket restriction against any use in pregnant women or allowing it in rare cases. Some panelists said the option should be left open for pregnant mothers who have high-risk COVID-19 and may have few other treatment options.

Dr. Janet Cragan, who backed the drug, said that even with tight restrictions some pregnant women would inevitably take the drug.

“I don’t think you can ethically tell a woman with COVID-19 that she can’t have the drug if she’s decided that’s what she needs,” a panel member and staffer with the Centers for Disease Control and Prevention. “I think the final decision has to come down to the individual woman and her provider.”

Merck's drug uses a novel approach to fight COVID-19: It inserts tiny errors into the coronavirus’ genetic code to stop it from reproducing. That genetic effect has raised concerns that the drug could spur more virulent strains of the virus. But FDA regulators said Tuesday that risk is theoretical and seems unlikely.

While Merck and its partner Ridgeback Biotherapeutics were the first to submit their COVID-19 pill to the FDA, rival drugmaker Pfizer is close behind with its own pill under review.

Pfizer’s drug is part of a decades-old family of antiviral pills known as protease inhibitors, a standard treatment for HIV and hepatitis C. They work differently than Merck’s pill and haven’t been linked to the kind of mutation concerns raised with Merck’s drug.

Pfizer said this week that its drug shouldn’t be affected by the omicron variant’s mutations.

The US government has agreed to purchase 10 million treatment courses of Pfizer’s drug, if it’s authorized. That’s more than three times the government’s purchase agreement with Merck for 3.1 million courses of molnupiravir.

Both drugs require patients to take multiple pills, twice a day for five days.

For the latest headlines, follow our Google News channel online or via the app.

Read more:

Explainer: How does Merck’s COVID-19 pill compare to Pfizer’s?

UK authorizes Merck coronavirus antiviral pill, first shown to treat COVID

Pfizer says its antiviral pill cuts risk of severe COVID-19 by 89 percent

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Tech

CyberArrow and Mobily Announced a Strategic Partnership for CyberArrow’s AI-Powered GRC at Black Hat 2023

In a groundbreaking collaboration, Mobily, one of the largest telecom companies in Saudi Arabia, and  CyberArrow , a leading UAE- based Compliance Automation Platform and Cyber Security Awareness Platform provider, proudly announced their strategic partnership at Black Hat 2023. This partnership marks a significant step towards revolutionizing the approach to compliance in the Kingdom of Saudi Arabia. The announcement cements Mobily as a strategic partner using CyberArrows AI-Powered GRC to boost cybersecurity compliance in the region. CyberArrows latest AI GRC was featured at the center of Black Hat 2023.  Key Highlights of the Strategic Partnership
The strategic partnership between CyberArrow and Mobily is a dynamic collaboration aimed at
reshaping the landscape of cyber security and compliance in Saudi Arabia. As a strategic partner,
Mobily helps organizations across Saudi Arabia enhance compliance processes and streamline
governance, risk, and compliance by utilizing CyberArrows AI-Powered GRC. This collaboration goes beyond physical presence; it symbolizes a shared vision for transformative advancements in compliance. The strategic partnership is designed to provide organizations in Saudi Arabia with intelligent solutions for navigating the complexities of cyber security and compliance with unprecedented efficiency. The partnership highlights the profound impact of integrating Artificial Intelligence (AI) into cyber security and compliance. Through cutting-edge solutions and strategic partnerships, CyberArrow demonstrates its commitment to leveraging AI as a catalyst for transformative change. As CyberArrow strategically partners with Mobily, these key messages echo their shared vision, amplifying the call for utilising CyberArrow’s AI-powered GRC platform and fortifying the digital landscapes of businesses in Saudi Arabia. “The collaboration with Mobily signifies more than just a partnership; it's a shared vision to make cyber security compliance accessible and robust for businesses in Saudi Arabia”, said Amar, Co-founder of CyberArrow

Continue Reading

World

TÜYAP will host the Carpet and Flooring Expo 2023

Around 400 companies will converge in Istanbul for Carpet and Flooring Expo
2023. This event, taking place from 5-8 December, will open new market avenues
for these companies. Türkiye, a nation responsible for crafting 40% of the worlds carpets, is playing host to this prestigious event.Türkiye, a key player in the global carpet industry, is gearing up to host the Carpet and Flooring Expo (CFE 2023) in Istanbul. This pivotal event, orchestrated by TÜYAP – the country’s foremost exhibition organizer – in partnership with the Istanbul Carpet Exporters’ Association and Southeastern Anatolia Carpet Exporters’ Association, will take place at the Istanbul Expo Centre from 5-8 December. The Expo, expected to attract around 400 companies from across the globe, will showcase an extensive array of products, providing an invaluable opportunity for manufacturers to tap into new markets. Türkiye has a 40% market share of global carpet production İlhan Ersözlü, General Manager of TÜYAP Fairs Productions Inc., highlights Türkiye’s significant role in the global carpet trade, stating, “Türkiye currently accounts for 17% of the worlds carpet trade volume. Through CFE 2023, we aim to foster new agreements, boosting our
export volume to 25%.” The global carpet market, valued at USD 64.99 billion in 2022, is anticipated to soar to USD 97.41 billion within a decade. Türkiye, producing nearly half of the worlds carpets, is a pivotal player in these global gatherings. 400 companies expected to participate in CFE 2023 Ersözlü stated, “Currently, our fair features nearly 400 participants, with 75% from Türkiye and 25% being international stakeholders. We’ve seen substantial interest from manufacturers in countries including Iran, China, England, Pakistan, Afghanistan, Uzbekistan, Russia, Indonesia, Morocco, Ukraine, Egypt, and Jordan. Our goal is to host one of the largest fairs in this sector.” He added, “The fair will display a spectrum of products, from traditional to contemporary designs. Registered visitors from 81 countries will have four days to explore these offerings. Additionally, well host discussions and workshops on future trends, designs, colours, and
recycling. Li Edelkoort, a renowned trend forecaster, will be present to deliver a talk titled ‘2025 Interior Trend and Colour Forecasts’ on 6 December at 16.00. This event will be an enormous source of inspiration for professionals in the carpet industry as well as designers, decorators, and
architects.”

Continue Reading

World

Gulf Scientific Corporation Achieves ISO 9001:2015 Certification, Setting New Standards in Quality Management

Gulf Scientific Corporation (GSC) has recently achieved a significant milestone by obtaining the ISO 9001:2015 certification, reinforcing its commitment to quality and excellence in the field of scientific solutions. This certification, awarded by the International Organization for Standardization (ISO), is a testament to GSCs dedication to meeting and exceeding global standards in its operations. ISO 9001:2015 is the latest version of the international standard for quality management systems, emphasizing a process-oriented approach to ensure organizations consistently deliver high-quality products and services. GSCs successful certification process reflects its adherence to rigorous quality management practices and continuous improvement initiatives. One key aspect of ISO 9001:2015 is its focus on customer satisfaction. GSCs commitment to understanding and meeting customer requirements is highlighted through this certification, as it demonstrates the company’s dedication to providing products and services that consistently meet or exceed customer expectations. This customer-centric approach is crucial in todays competitive business environment, where customer satisfaction plays a pivotal role in the success of any organization. Furthermore, the ISO certification positions Gulf Scientific Corporation as a reliable and trustworthy partner for businesses seeking high-quality scientific equipment and solutions. It enhances the company’s reputation and opens doors to new opportunities and collaborations on a global scale. By implementing a robust quality management system, GSC will also be better equipped to manage risks and seize opportunities, ensuring the organizations resilience and adaptability in a dynamic market. Internally, the certification process has led to improved operational efficiency within GSC. Through a thorough examination of its processes and procedures, the company has already identified areas for enhancement and optimization. This commitment to continuous improvement not only aligns with
ISO 9001:2015 requirements but also positions GSC as a forward-thinking and adaptive organization. Gulf Scientific Corporations attainment of the ISO 9001:2015 certification underscores its dedication to quality, customer satisfaction, and ongoing improvement. This achievement not only enhances GSCs reputation in the industry but also instils confidence in its customers, partners, and stakeholders. As GSC continues to uphold these high standards, the ISO 9001:2015 certification serves as a symbol of the company's commitment to excellence in the ever-evolving landscape of scientific solutions.

Continue Reading

Trending